Memorial Sloan Kettering Cancer Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Memorial Sloan Kettering Cancer Center sits in the top decile of US sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count).
Memorial Sloan Kettering Cancer Center: 1,884 sponsored US clinical trials, 327 recruiting.
Memorial Sloan Kettering Cancer Center sponsors 1,884 registered US clinical trials on ClinicalTrials.gov, 327 of them currently recruiting, and 1,104 completed. 75 of these trials are in Phase 3-4 (later-stage) and 1,101 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 98 trials.
Top-decile sponsor footprint
Memorial Sloan Kettering Cancer Center ranks in the top decile of sponsors by registered trial count (#6 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
1,884 total, page 14 of 38
Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer
NCT01688492
Food: A Three-Arm Study Examining Food Insecurity Interventions
NCT01603316
Evaluate The Utility Of 124I-cG250 for The Early Detection Of Response to Therapy In Patients With Metastatic Renal Cell Carcinoma
NCT01582204
Attention and Interpretation Modification (AIM) for Fear of Cancer Recurrence: An Intervention Development Study
NCT01517945
Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases
NCT01470105
Communication Skills Intervention to Promote Transition Into Survivorship
NCT01483664
Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls
NCT01453660
In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
NCT01430390
Measuring Patient Expectations for Thyroid Surgery
NCT01412762
Trial of Modifications to Radical Prostatectomy
NCT01407263
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study
NCT01266096
PET Imaging of Cancer Patients Using 124I-PUH71: A Pilot Study
NCT01269593
Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy
NCT01223248
Partial Breast Irradiation (PBI) Using 40 Gy for Select Patients With Early Invasive or Noninvasive Breast Cancer
NCT01203839
Rehabilitation of Cognitive Changes in Breast Cancer Survivors
NCT01182506
Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor
NCT01189643
Promoting Breast Cancer Screening in Women Who Survived Childhood Cancer
NCT01579552
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
NCT01140373
Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
NCT01141309
Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life
NCT01134172
Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
NCT01044069
Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma
NCT01025089
Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome
NCT01494324
Genomic Structural Variation in Cancer Susceptibility
NCT00996710
Understanding the Psychosocial Needs of Parents Who Have Lost a Child to Cancer
NCT00968500
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
NCT00911560
Study of Radiation Exposure and Bilateral Breast Cancer
NCT00903591
Dose Escalation Study Using Ultra-Hypofractionated, Image-Guided, Intensity-Modulated Radiotherapy in Prostate Cancer
NCT00911118
A Genotype-Phenotype Urothelial Cancer Registry
NCT00902590
Adolescent and Young Adult Cancer Survivors: Identity Development
NCT00832325
Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
NCT00715611
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
NCT00335816
Quality of Life in Patients With Bladder Cancer
NCT00745355
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life
NCT00639301
Risk Factors for Endometrial Cancer in Black Women
NCT00514254
Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver
NCT00492999
Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
NCT00466531
Penile Injection Anxiety
NCT00582231
The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older
NCT00579072
Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity
NCT00393783
Dynamic Contrast Enhanced MRI (DCE-MRI) Diffusion Weighted MRI (DW-MRI) and Magnetic Resonance Spectroscopy (MRS) of Head and Neck Tumors
NCT00581906
Genetic Susceptibility to Lung Cancer in Never Smokers
NCT00597636
Multi-Organ Screening Recommendations in Patients With Lynch Syndrome
NCT00582296
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
NCT00077285
Smoking Cessation Intervention for Cancer Patients
NCT00575718
A Randomized Clinical Trial Assessing Smoking Cessation Interventions In Dental Clinic Smokers
NCT00591175
Investigating Mechanisms to Explain Age Associated Differences in Quality of Life Among Breast Cancer Patients
NCT00582478
Estrogen, Diet, Genetics and Endometrial Cancer
NCT00587886
Collection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract
NCT00582647
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
NCT00579514
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 461 |
| Phase 2 | 640 |
| Phase 3 | 67 |
| Phase 4 | 8 |
Therapeutic Areas
What is open in the Memorial Sloan Kettering Cancer Center pipeline
327 recruiting of 1,884 indexed (17% open); 1,104 completed (59%).
Phase mix: 75 late (III/IV) vs 1,101 early (I/II) (early-phase heavy).
Top condition: Breast Cancer (98 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.